As of Feb 21, 2025, BioNTech SE's Discounted Cash Flow (DCF) valuation estimates its share price at $231.7. This suggests it may be undervalued by 93.0% compared to its current price of around $120.0, using a WACC of 7.6% and growth rates of 3.0%.
As of Feb 21, 2025, BioNTech SE's Weighted Average Cost of Capital (WACC) is approximately 7.6%.
As of Feb 21, 2025, BioNTech SE's Enterprise Value (EV) is approximately €36.9B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.